Ignite Creation Date:
2025-12-24 @ 7:35 PM
Ignite Modification Date:
2026-06-22 @ 9:10 PM
Study NCT ID:
NCT01507103
Status:
COMPLETED
Last Update Posted:
2017-01-13
First Post:
2012-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tecemotide (L-BLP25) in Rectal Cancer
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Rectal Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Tecemotide (L-BLP25) | View |
| None | Cyclophosphamide (CPA) | View |
| None | Mode of action | View |
| None | Neoplasms | View |
| None | Neoplasms by Site | View |
| None | Carcinomas | View |
| None | Antineoplastic Agents | View |
| None | Neoadjuvant | View |
| None | Radiotherapy Pharmacologic Actions | View |
| None | Immunosuppressive Agents | View |
| None | Immunologic Function | View |
| None | Therapeutic Uses | View |
| None | Molecular Mechanisms of Pharmacological Action | View |